Emtora Biosciences is focused on the commercialization of eRapa™, a novel formulation of rapamycin designed to prevent the onset and recurrence of various cancers. This innovative drug aims to address early-stage cancers and precancerous conditions, particularly targeting non-muscle invasive bladder cancer, low-grade prostate cancer, and Familial Adenomatous Polyposis (FAP). eRapa™ is engineered to enhance the bioavailability of rapamycin, which has historically faced challenges such as low absorption and significant toxicity. By utilizing a proprietary micro-encapsulation technology, eRapa™ protects the active ingredient from degradation in the stomach, allowing for targeted delivery to the lower intestines and colon, where it can exert its therapeutic effects.

The mechanism of action of eRapa™ involves modulation of the mTOR pathway, which plays a critical role in regulating cell growth, proliferation, and survival. This targeted approach not only aims to suppress cancerous growth but also rejuvenates the immune system, potentially extending health span and life span. Emtora's clinical development pipeline includes ongoing trials for FAP and non-muscle invasive bladder cancer, with promising preclinical results indicating significant disease suppression and improved survival rates in animal models. The company has received substantial grants to support its research and has achieved orphan drug designation for FAP, highlighting its commitment to addressing unmet medical needs in cancer prevention and treatment.

United States

Emtora Biosciences is a life science company developing a novel formulation of rapamycin, eRapa™, for use in preventing the onset and recurrence of cancer.  A Phase 1b safety and dosing clinical trial is underway in early stage prostate cancer patients.  A pilot efficacy study in Familial Adenomatous Polyposis (FAP) is planned for late 2019.

Emtora Biosciences

Company Details